• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Parry, M. G.
    Nossiter, J.
    Morris, M.
    Sujenthiran, A.
    Skolarus, T. A.
    Berry, B.
    Nathan, A.
    Cathcart, P.
    Aggarwal, A.
    van der Meulen, J.
    Trinh, Q. D.
    Payne, H.
    Clarke, N. W.
    Show allShow less
    Affiliation
    Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Introduction The treatment of prostate cancer varies between the United States (US) and England, however this has not been well characterised using recent data. We therefore investigated the extent of the differences between US and English patients with respect to initial treatment. Methods We used the Surveillance, Epidemiology, and End Results (SEER) database to identify men diagnosed with prostate cancer in the US and the treatments they received. We also used the National Prostate Cancer Audit (NPCA) database for the same purposes among men diagnosed with prostate cancer in England. Next, we used multivariable regression to estimate the adjusted risk ratio (aRR) of receiving radical local treatment for men with non-metastatic prostate cancer according to the country of diagnosis (US vs. England). The five-tiered Cambridge Prognostic Group (CPG) classification was included as an interaction term. Results We identified 109,697 patients from the SEER database, and 74,393 patients from the NPCA database, who were newly diagnosed with non-metastatic prostate cancer between April 1st 2014 and December 31st 2016 with sufficient information for risk stratification according to the CPG classification. Men in the US were more likely to receive radical local treatment across all prognostic groups compared to men in England (% radical treatment US vs. England, CPG1: 38.1% vs. 14.3% – aRR 2.57, 95% CI 2.47–2.68; CPG2: 68.6% vs. 52.6% – aRR 1.27, 95% CI 1.25–1.29; CPG3: 76.7% vs. 67.1% – aRR 1.12, 95% CI 1.10–1.13; CPG4: 82.6% vs. 72.4% – aRR 1.09, 95% CI 1.08–1.10; CPG5: 78.2% vs. 71.7% – aRR 1.06, 95% CI 1.04–1.07) Conclusions Treatment rates were higher in the US compared to England raising potential over-treatment concerns for low-risk disease (CPG1) in the US and under-treatment of clinically significant disease (CPG3-5) in England.
    Citation
    Parry MG, Nossiter J, Morris M, Sujenthiran A, Skolarus TA, Berry B, et al. Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. Prostate Cancer Prostatic Dis. 2022.
    Journal
    Prostate Cancer Prostatic Dis
    URI
    http://hdl.handle.net/10541/625008
    DOI
    10.1038/s41391-021-00482-6
    PubMed ID
    35001083
    Additional Links
    https://dx.doi.org/10.1038/s41391-021-00482-6
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1038/s41391-021-00482-6
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation.
    • Authors: Parry MG, Cowling TE, Sujenthiran A, Nossiter J, Berry B, Cathcart P, Aggarwal A, Payne H, van der Meulen J, Clarke NW, Gnanapragasam VJ
    • Issue date: 2020 May 28
    • The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.
    • Authors: Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, Lophatananon A
    • Issue date: 2018 Feb 28
    • Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer.
    • Authors: Gnanapragasam VJ, Barrett T, Thankapannair V, Thurtle D, Rubio-Briones J, Domínguez-Escrig J, Bratt O, Statin P, Muir K, Lophatananon A
    • Issue date: 2019 Nov
    • Issue date: 2021 Dec
    • The Effects of O(6)-methyl Guanine DNA-methyl Transferase Promotor Methylation and CpG1, CpG2, CpG3 and CpG4 Methylation on Treatment Response and their Prognostic Significance in Patients with Glioblastoma.
    • Authors: Yildiz OG, Aslan D, Akalin H, Erdem Y, Canoz O, Aytekin A, Ozoner S, Dundar M
    • Issue date: 2020 Jun
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.